Design and endpoints of clinical trials in hepatocellular carcinoma.

@article{Llovet2008DesignAE,
  title={Design and endpoints of clinical trials in hepatocellular carcinoma.},
  author={Josep M Llovet and Adrian M Di Bisceglie and Jordi Bruix and Barnett S. Kramer and Riccardo A Lencioni and Andrew X. Zhu and Morris Sherman and Myron Schwartz and Michael Lotze and Jayant Talwalkar and Gregory J. Gores},
  journal={Journal of the National Cancer Institute},
  year={2008},
  volume={100 10},
  pages={698-711}
}
The design of clinical trials in hepatocellular carcinoma (HCC) is complex because many patients have concurrent liver disease, which can confound the assessment of clinical benefit. There is an urgent need for high-quality trials in this disease. An expert panel was convened by the American Association for the Study of Liver Diseases to develop guidelines that provide a common framework for designing trials to facilitate comparability of results. According to these guidelines, randomized phase… CONTINUE READING
Highly Influential
This paper has highly influenced 48 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 675 extracted citations

Similar Papers

Loading similar papers…